ViaCyte to Present at Biotech Showcase in San Francisco
Press release from the issuing company
Monday, January 5th, 2015
ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced that Dr. Paul Laikind, President and Chief Executive Officer, will present and participate in moderated panel discussions at the upcoming Biotech ShowcaseTM taking place January 12-15, 2015 in San Francisco. The presentation details are as follows:
|
Session: |
State of the Regenerative Medicine and Advanced Therapies Briefing |
|
Panel: |
"Dose, Delivery, Data: Understanding the Three D's of Advanced Therapy Drug Development" |
|
Date/Time: |
Monday, January 12th at 9:05 a.m. PST |
|
Session: |
Company Presentation |
|
Date/Time: |
Monday, January 12th at 11:30 a.m. PST |
|
Session: |
JDRF-sponsored Workshop |
|
Panel: |
"Type 1 Diabetes: Novel Therapies, Devices and Diagnostics on the Horizon" |
|
Date/Time: |
Tuesday, January 13th at 8:00 a.m. PST |
All of the presentations will take place at the Parc55 Wyndham San Francisco in Union Square. To register for the events or for more information, please visit Biotech Showcase's website: http://www.ebdgroup.com/bts/program/index.php
Dr. Laikind will review recent progress with the company's VC-01™ islet replacement product candidate for the treatment of type 1 diabetes, which recently entered the clinical phase of development. A Phase 1/2 trial to assess safety, tolerability, and efficacy of the product in human subjects with diabetes, called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1, was launched in September 2014, and the first implant was announced in October 2014.
